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Shifting policies towards legalisation of cannabis for therapeutic and recreational use raise significant 
ethical issues for health-care providers seeking evidence-based recommendations. We investigated 
whether heavy cannabis use is associated with persistent harms to the hippocampus, if exposure to 
cannabidiol offers protection, and whether recovery occurs with abstinence. To do this, we assessed 111 
participants: 74 long-term regular cannabis users (with an average of 15.4 years of use) and 37 non-user 
healthy controls. Cannabis users included subgroups of participants who were either exposed to 
Δ9-tetrahydrocannabinol (THC) but not to cannabidiol (CBD) or exposed to both, and former users with 
sustained abstinence. Participants underwent magnetic resonance imaging from which three measures 
of hippocampal integrity were assessed: (i) volume; (ii) fractional anisotropy; and (iii) N-acetylaspartate 
(NAA). Three curve-fitting models across the entire sample were tested for each measure to examine 
whether cannabis-related hippocampal harms are persistent, can be minimised (protected) by exposure 
to CBD or recovered through long-term abstinence. These analyses supported a protection and recovery 
model for hippocampal volume (P=0.003) and NAA (P=0.001). Further pairwise analyses showed that 
cannabis users had smaller hippocampal volumes relative to controls. Users not exposed to CBD had 11% 
reduced volumes and 15% lower NAA concentrations. Users exposed to CBD and former users did not 
differ from controls on any measure. Ongoing cannabis use is associated with harms to brain health, 
underpinned by chronic exposure to THC. However, such harms are minimised by CBD, and can be 
recovered with extended periods of abstinence. 
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ORIGINAL ARTICLE
Hippocampal harms, protection and recovery following
regular cannabis use
M Yücel1,7, V Lorenzetti1,7, C Suo1, A Zalesky2, A Fornito1, MJ Takagi2, DI Lubman3 and N Solowij4,5,6,7
Shifting policies towards legalisation of cannabis for therapeutic and recreational use raise significant ethical issues for health-care
providers seeking evidence-based recommendations. We investigated whether heavy cannabis use is associated with persistent
harms to the hippocampus, if exposure to cannabidiol offers protection, and whether recovery occurs with abstinence. To do this,
we assessed 111 participants: 74 long-term regular cannabis users (with an average of 15.4 years of use) and 37 non-user healthy
controls. Cannabis users included subgroups of participants who were either exposed to Δ9-tetrahydrocannabinol (THC) but not to
cannabidiol (CBD) or exposed to both, and former users with sustained abstinence. Participants underwent magnetic resonance
imaging from which three measures of hippocampal integrity were assessed: (i) volume; (ii) fractional anisotropy; and
(iii) N-acetylaspartate (NAA). Three curve-fitting models across the entire sample were tested for each measure to examine whether
cannabis-related hippocampal harms are persistent, can be minimised (protected) by exposure to CBD or recovered through
long-term abstinence. These analyses supported a protection and recovery model for hippocampal volume (P= 0.003) and
NAA (P= 0.001). Further pairwise analyses showed that cannabis users had smaller hippocampal volumes relative to controls. Users
not exposed to CBD had 11% reduced volumes and 15% lower NAA concentrations. Users exposed to CBD and former users did not
differ from controls on any measure. Ongoing cannabis use is associated with harms to brain health, underpinned by chronic
exposure to THC. However, such harms are minimised by CBD, and can be recovered with extended periods of abstinence.
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INTRODUCTION
Despite the promise of cannabis as a therapeutic agent for a
number of conditions, long-term, regular cannabis use has
been associated with substantial cognitive, mental health and
neurobiological harms,1 particularly to the hippocampal region.2,3
Yet, there is very little data on whether these brain-related harms
are permanent, can recover with abstinence or are influenced by
the proportion of Δ9-tetrahydrocannabinol (THC) and cannabidiol
(CBD) in the cannabis consumed. Most of the negative effects
(for example, impaired cognition, anxiety and psychotic-like
experiences)4,5 are attributed to THC, while CBD has amelio-
rating, antipsychotic/anxiolytic6,7 and potentially neuroprotective
properties.8,9
Given the recent legalisation of cannabis in many countries, and
ongoing debate regarding its potential impact on public health,1 it
is critical that we understand whether prolonged exposure to THC
is associated with persistent hippocampal harms (or recovers
following abstinence) and whether CBD offers some protection.
We sought to address these issues using magnetic resonance
imaging (MRI) to compare the hippocampal integrity of long-term,
regular cannabis users who were either exposed to THC but not to
CBD (CBD group) or exposed to both THC and CBD (CBD+ group),
with matched non-using healthy controls. We conducted similar
comparisons for regular cannabis users with unknown exposure to
CBD (CBDx group), as well as former users who were abstinent for
an extended period (Former Users group).
We predicted the following: (i) there would be neurobiological
harms associated with long-term and heavy cannabis exposure;
(ii) the harms would not be present in individuals who use




It is notoriously difficult to recruit samples of long-term and heavy
cannabis users without a range of potential confounds (such as psychiatric
comorbidity and other drug use) into studies of this type, particularly
where extensive MRI scans and other lengthy assessments are required.
This strategy often results in smaller sample sizes than may be desired. We
have nevertheless recruited to this study 74 well-characterised, extensively
screened, psychiatrically healthy individuals with chronic exposure to
cannabis (40 males and 34 females) and minimal exposure to other illicit
drugs (o50 lifetime occasions; median values for lifetime occasions of use:
n= 0 for benzodiazepines and sedatives, cocaine, inhalants, opiates and
other drugs; n= 5 for amphetamines and ecstasy; and n=2 for
hallucinogens), from the general community.
Inclusion criteria for all participants were as follows: 19 to 55 years of
age; right handedness; English as a first language; normal or corrected-to-
normal visual acuity; and ability to travel to the assessment sites. Cannabis
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users were included if they used cannabis regularly for a minimum of
2 years, with ‘regular use’ being defined as at least twice a month; were
willing to abstain from cannabis for at least 12 h before attending either
assessment session to ensure that examination would occur in a non-
intoxicated, non-abstinent state; and were willing to refrain from using
substances other than cannabis in the month before assessment. Exclusion
criteria for all participants were as follows: presence of neurological
disorders or serious head injury; personal psychiatric histories requiring
treatment; prolonged use of psychotropic medications; contraindications
for MRI (for example, metal implants and claustrophobia); and significant
regular use of substances other than cannabis.
Cannabis users were composed of four subgroups (Table 1): (i) current
users testing positive for urinary cannabinoid metabolites, but unknown
proportional exposure to CBD due to unavailability of hair samples for
analysis (CBDx, n= 19); (ii) current users exposed to THC but not to CBD
(from analysis of hair samples reflecting past 3-month exposure; CBD− ,
n= 30); (iii) current users exposed to both THC and CBD, ascertained via
hair analysis (CBD+, n=12); and (iv) former regular cannabis users
abstinent by self-report for a mean 29 (s.d. = 64) months, with no
cannabinoid metabolites detected in hair (n=9) or urine (Former Users;
n= 13). (Hair samples were available for eleven former users; nine had no
cannabinoid metabolites detected. Two former users had cannabinoid
metabolites detected in hair but they had ceased using within the past
month and had no metabolites detected in urine. Hair samples were not
available for two former users.) Current cannabis use was also confirmed
by urinalysis in the users of groups (ii) and (iii). Of note, in current users
past-year dosage, measured in cumulative number of cones (that is,
1 joint = 3 cones), was significantly and positively correlated with THC
levels in hair (R=0.35, P= 0.040). We also recruited 37 non-cannabis using
controls (18 males and 19 females), who did not test positive for urinary
cannabinoid metabolites. The research protocol was approved by the
relevant institutional review boards or ethics committees, and all
participants gave written informed consent.
Substance use measures
We obtained data on past-month substance use via the Timeline Follow-
back Procedure,10 and comprehensively examined lifetime use of any
psychoactive substance other than cannabis using the Substance Use
History tool (Orygen Youth Health Research Centre, Melbourne, VIC,
Australia.11–14 Alcohol or cannabis use were measured separately via the
Alcohol Use Disorder Identification Test15 and Cannabis Use Interview,
respectively. Results from urine toxicology tests corroborated self-reported
substance use.
MRI protocol and procedures
Each participant underwent a comprehensive structured interview and
psychiatric assessment,16 and a series of high-field (3T Siemens TIM Trio,
Siemens, Munich, Germany, 32 channel head coil) MRI scans involving
structural, diffusion and spectroscopic sequences. From these measures,
we derived three well-validated indices of hippocampal integrity:
(1) volume; (2) fractional anisotropy; and (3) N-acetylaspartate (NAA).
These measures provide a detailed assay of hippocampal integrity at the
level of macrostructure, microstructure and neurochemistry (Figure 1).
Structural imaging: volume
Hippocampal volume was measured by manual tracing on T1-weighted
structural magnetic resonance images acquired in the sagittal plane with a
high-resolution three-dimensional Magnetization Prepared Rapid Acquisi-
tion Gradient Echo (MP-RAGE) imaging sequence (Time Repetition=
1900 ms, Time Echo= 2.15 ms, Field of view= 256 mm). Each participant’s
raw image was bias corrected, skull stripped, rigid-body co-registered to
the standard Montréal Neurological Institute template and re-sliced
into 1 × 1× 1 mm3 spatial resolution using tri-liner interpolation in SPM8
(Wellcome Trust Centre for Neuroimaging, London, UK). Bilateral hippo-
campi were traced by an expert (VL), blind to group status, from coronally
displayed MRI images using ANALYZE (version 11, Mayo Clinic, Rochester,
MN, USA) according to previously validated protocols.2 Hippocampal
volume was defined as the mean of both left and right hippocampi. Inter-
rater and intra-rater reliabilities (VL and SW) were assessed using the
intraclass correlation coefficient (absolute agreement) via highly reliable
and valid protocols.2 In all volumetric measures of the hippocampus, inter-
rater and intra-rater reliabilities were consistently intraclass correlation
coefficient 40.85. Intracranial volume was calculated by summing the
volumes of grey matter, white matter and cerebrospinal fluid, after
segmentation in raw images using SPM8, and was then used to adjust
hippocampal volumes by the same method described previously by
Erickson et al.17
Diffusion imaging: fractional anisotropy
Fractional anisotropy was measured in two regions of interest, bilaterally—
the fimbria and the hippocampal portion of the cingulum bundle—
defined according to the JHU-ICBM white-matter atlas.18 The white-matter
regions of interest we have considered are based on our previous whole-
brain study of axonal disruptions in a large sample of cannabis users.3
In this previous study, the fimbria and hippocampal portion of the
cingulum bundle were identified as comprising significantly fewer
streamlines in the group of cannabis users. As such, these white-matter
structures were selected as regions of interest for the present study.
Considering additional regions without any a priori hypothesis was
avoided to reduce the scale of the multiple comparisons problem. Given
the sample size, we opted to minimise the number of multiple
comparisons by performing inference only on regions for which we had
prior evidence for an effect.
Forty-two diffusion-weighted volumes were acquired using a spin-echo
echo-planar imaging sequence with the following parameters:
b-value, 2000 s mm− 1; 54 consecutive axial slices of 2.3-mm thickness;
104 × 104 image matrix with an in-plane voxel resolution of 2.3 × 2.3 mm;
field of view, 24 × 24 cm; repetition time, 7000 ms; echo time, 96 ms; and
flip angle, 90°. The diffusion-imaging data were foremost corrected
for eddy current distortions by linearly registering each diffusion-weighted
volume to the first non-diffusion-weighted volume acquired. Fractional
anisotropy images were computed with a least squares fit of the
diffusion tensor, carefully inspected for artefacts, warped to Montreal
Neurological Imaging standard space and resampled to a 1 × 1× 1 mm3
spatial resolution. Fractional anisotropy values were averaged over all
voxels encapsulated by each region of interest to yield a tract-specific
measure of white-matter integrity. These steps were implemented using
tools in the FMRIB Software Library (www.fmrib.ox.ac.uk/fsl/) with standard
options.
Spectroscopic imaging: N-acetylaspartate
NAA, a marker of neuronal viability, was acquired from the left
hippocampus using a standard short-echo point-resolved magnetic
resonance spectroscopy sequence (repetition time 3000 ms, echo time
30 ms, averages 128; with a nominal voxel size ~ 3 cm3 placed to
encompass the entire hippocampus). The boundaries of the voxel were,
posteriorly, placed ~ 5 mm anterior to the hippocampus tail; inferiorly,
located ~ 1 mm above the subiculum; and medially, located ~ 3 slices
lateral to the fimbria. We excluded low-quality spectral data (29 out of 111
images) by (i) discarding images with signal-to-noise ratios o6 or broader
linewidth, full width at half maximum40.1 Hz; and (ii) using the commonly
accepted Cramer–Rao lower bound criterion of 15% for NAA total to
further reject low-quality spectra.19 The quantity of excluded images (26%)
is in line with expectations in this notoriously difficult brain region to
assay.20 A sample magnetic resonance spectroscopy spectrum of the
hippocampus is displayed in Figure 2.
Of the remaining spectra, the parameters used for this study provided
robust signals both for all five groups, and no significant group differences
for any measure, with an average signal-to-noise ratio of 9.29 (s.d. = 1.46),
full width at half maximum of 0.06 p.p.m. (s.d. = 0.01) and Cramer–Rao
lower bounds of 5.5 (s.d. = 1.38). The volume fractions of different tissue
types were calculated by initially segmenting T1 images in the raw space
using SPM8. Then, a mask (NIfTI format) of the spectroscopic voxel was
reconstructed using the dimension, placement and angulation information
from magnetic resonance spectroscopy header information. As both
images are in the scanner co-ordinates, we co-registered the spectroscopic
voxel image to the T1 image and extracted the volume of grey matter,
white matter and cerebrospinal fluid within the voxel. The fraction of
cerebrospinal fluid was used to correct for the partial volume effect to
obtain absolute metabolite tissue concentration in millimole per litre
(mM l− 1). Spectroscopic data were quantified using LCModel (version 6.3,
LCMODEL, Oakville, ON, Canada), via a combination of water-suppressed
and unsuppressed spectra, to compute the absolute quantification of each
metabolite. This was achieved by fitting the experimental spectrum with a
group of basis sets, each of which is the spectrum of a specific metabolite
or macromolecule.19
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Statistical analyses
All analyses were performed using SPSS (version 22.0, IBM, Armonk, NY,
USA). All variables met the assumptions of normal distribution and
homogeneity by Shapiro–Wilk’s and Levene’s tests, respectively, enabling
the use of parametric tests.
Group comparisons for demographic (age and gender), substance use
(alcohol and tobacco), psychopathological symptoms (anxiety and
depressive), general functioning, intelligence quotient and gross brain
measures (intracranial volume and whole-brain volume) were conducted
by a series of t-tests (and a χ2-test for gender). Variables that differed
between groups (level of alcohol and tobacco use, anxiety and depressive
symptoms, general functioning and intelligence; Table 1) were included,
together with age and intracranial volume, as covariates.
Curve-fitting and polynomial contrasts were applied to the data across
the five groups to test the hypotheses that hippocampal harms in regular
cannabis users (1) are persistent (linear curve), (2) can be minimised by
exposure to CBD but not recovered by abstinence (cubic curve) and (3) can
be both minimised by CBD and recovered through long-term abstinence
(quadratic curve; Figure 3). Importantly, we tested these models for
each of the three measures of hippocampal integrity (volume, fractional
anisotropy (FA) and NAA). We hypothesised that in the cannabis
group with unknown proportional exposure to THC versus CBD (CBDx)
we would replicate our2 and others’21,22 previous findings of reduced
hippocampal volume in cannabis users and that this group would have
reduced neuronal integrity reflected by NAA and FA relative to controls. As
such, the CBDx group (presumably reflecting a mixed THC and CBD
exposed participants) was placed first in the model after controls. On the
basis of previous literature, we predicted the poorest outcomes for
the CBD− group, whereas outcomes for CBD+ and Former Users were
less predictable. The order of their placement enabled testing of, and
distinguishing between, the three modelling functions of persistence,
protection and recovery. To correct for multiple comparisons and type I
error we used an adjusted critical significance threshold of Po0.017
(0.05/3).
To better understand the nature of these findings, we conducted
separate analyses of covariance with group as the between-group factor
for each hippocampal feature (volume, fractional anisotropy or NAA,
respectively), which was used as dependent variable. Significant
effects were further investigated using planned pairwise group compa-
risons, and calculated effect size (ES) (Cohen’s d) for all between-group
analyses.
Post hoc power analysis
G*Power (University of Dusseldorf, Duesseldorf, Germany) was used to
conduct a sensitivity analysis for the analysis of covariance analysis. Results
showed that a total sample size of 111 enabled power of 0.80 to detect
small–medium ES of at least 0.38.
RESULTS
The results revealed a significant quadratic pattern for both
hippocampal volume (P= 0.003) and NAA (P= 0.001; Figure 4a and
b). Group-wise analyses of covariance for hippocampal volume (a)
revealed a main effect of group, F4, 99 = 4.60, P= 0.002, ES = 0.88.
Post hoc pairwise comparisons showed that relative to controls,
the CBDx group had significantly smaller hippocampi (7%
reduction, P= 0.029, ES = 0.68) while the CBD− group showed
the largest relative reduction in volume (11% smaller, Po0.0001,
ES41.0). Former Users did not differ from controls (3% smaller
volume in Former Users, P= 0.26, ES = 0.35) and had significantly
larger volumes than the CBD− group (8% increase, P= 0.023,
ES = 0.79). For hippocampal NAA concentrations (b), there was a
main effect of group, F4, 70 = 3.41, P= 0.013, ES = 0.88. Post hoc
tests showed that NAA levels were significantly reduced in the
CBD− group relative to controls (14% smaller, P= 0.003, ES = 0.96)
and relative to Former Users (16% smaller, P= 0.003, ES41.0).
Former Users also had higher NAA levels than the CBDx group
(P= 0.028, ES = 0.88) and did not differ from controls (P= 0.35,
ES = 0.18). There was no overall significant group difference for
hippocampal FA values (main effect F4, 99 = 0.99, P= 0.42, ES = 0.40;
c). The ES of all three analyses of covariance (that is, Figure 4a,
volume; b, NAA; and c, FA) ranged from 0.40 to 0.88.
Overall, the results support our prediction of reductions
in hippocampal integrity in regular cannabis users (Figure 4).
The results are also consistent with a protection and recovery
model, indicating that cannabis-related hippocampal harms









Figure 1. Multimodal assay of the medial temporal grey matter and white matter, and biochemistry. (a) Coronal view; (b) sagittal view.
Concurrent (within subjects) assay of fractional anisotropy from the fimbria and cingulum–hippocampus white-matter fibres (red); anatomical
grey-matter volume of the hippocampus proper (green); and N-acetylaspartate from a voxel positioned over the hippocampus (yellow). Lower
panels show a close-up rendered image to illustrate the relative positions and associations of the medial temporal regions assayed.
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DISCUSSION
We believe this is the first multimodal MRI investigation of
prolonged THC and CBD exposure or abstinence on hippocampal
integrity in current and former cannabis users, respectively. We
confirmed that hippocampal volume is reduced in long-term
cannabis users, and found that this atrophy can be restored
following prolonged abstinence. Moreover, we show for the first
time that both hippocampal volume and neurochemistry are
reduced to the greatest extent in users exposed to THC without
CBD. In contrast, current users of cannabis containing CBD, as well
as former users, show no structural or neurochemical hippocampal
differences compared with controls. These findings are consistent
with suggestions that CBD may be neuroprotective, perhaps
through its role in synaptic plasticity and/or neurogenesis.23
The findings have implications for how we conceptualise the
long-term effects of cannabis use on the human brain. Our
findings suggest that not all cannabis users experience adverse
brain and behavioural outcomes24,25 as cannabinoid compounds
such as CBD may have a role in minimising harm. Indeed, previous
reports have suggested that CBD may ameliorate psychotic and
Figure 3. Theoretical models of cannabis-related neurobiological harms. Linear, cubic and quadratic models were tested for each of the three
measures of hippocampal integrity. The illustrations are theoretical models of data points that would support each hypothesis of persistence
(a), protection (b) and recovery (c). The highlighted window shows the portion of each model to which data from this study contributes new
knowledge.
Figure 2. An example of LCModel output for magnetic resonance spectroscopy spectrum from the hippocampus. The red solid line indicates
the summary of all fitted metabolites’ peaks. For N-acetylaspartate (NAA), the major peak is located at 2.02 p.p.m. Mean NAA across all groups
(N= 82) was 6.35 (s.d.= 0.97). Separately for each group, mean NAA values were as follows: healthy control, 6.40 (s.d.= 0.89); CBDx,
6.28 (s.d.= 0.90); CBD− , 5.82 (s.d.= 1.11); CBD+, 6.54 (s.d.= 0.76); and Former Users, 6.94 (s.d.= 0.86).
Cannabis-related brain harms, protection and recovery
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adverse cognitive effects of THC.6,21,26–28 For instance, participants
pretreated with CBD experience significantly reduced psychoto-
genic and anxiogenic effects of THC.26–31 At a neural level, CBD
exerts opposing effects to THC on brain function and connectivity
in regions that are high in cannabinoid receptors including the
hippocampus.27,29–33 Although the relative contribution of THC
and CBD to overall brain harm remains unclear, we provide
preliminary evidence that these major cannabinoid compounds
have a distinct role in hippocampal structural and neurochemical
integrity following chronic exposure to cannabis.
The role of CBD in reducing brain and behavioural harms of
cannabis warrants consideration when discussing legalisation
related to the potency and composition of commercial cannabis.
Whether its mandatory inclusion as a public health directive
would protect against poor functional outcomes, such as severe
mental health problems or cognitive decline among regular
cannabis users, remains to be substantiated.
In former users, hippocampal integrity was comparable to
controls. This contrasts results from other studies of abstinent
former users that have found persistent effects of heavy use on
brain function and cognition.34–40 In a prospective study of 1037
people from birth to age 38,41 persistent cannabis exposure
(assessed at ages 18, 21, 26, 32 and 38 years) was associated with
significant decline in neuropsychological performance. Of note,
these cognitive impairments did not show significant improve-
ment following reduction of use or complete abstinence (41 year
cessation in some cases). In the context of our data, these findings
suggest that functional deficits may persist in abstinent former
users, despite apparent recovery of hippocampal integrity.
Strengths and limitations
The use of hair sample analysis to define groups exposed or
non-exposed to CBD is limited in that it only provides information
on exposure over the prior 3 months (when 3 cm of hair is
analysed). Variable exposure over the lifetime cannot be estimated
although it is likely that CBD levels in cannabis were higher in
previous decades.42 Unfortunately, hair sample analysis was not
available for former users, however there was no particular reason
for them to overstate their durations of abstinence and hence
their self-reports are assumed to be reliable. We also acknowledge
the limitations of a cross-sectional design and the modest sample
size when examining subgroup differences. It has to be
recognised that this is one of the largest samples to date in the
international literature and that there are immense difficulties in
recruiting abstinent, former users with a long history of regular
cannabis use (that is, ~ 15 years), and without any comorbid
substance use and/or mental health problems to complex and
demanding studies of this type. At the same time, strict exclusion
criteria were also the strength of our study; recruitment of
74 ‘clean’ cannabis users enabled our modelling approach to
address the gaps in the human literature regarding the
neuroprotective and therapeutic potentials of CBD and possible
recovery with abstinence.
In conclusion, it seems that CBD and extended abstinence
from cannabis may, respectively, protect or restore hippocampal
integrity. With ~ 200 million users worldwide, these findings
inform the current debate regarding the legalisation, commercia-
lisation and therapeutic application of cannabis.
Figure 4. Scatter plots illustrate hippocampal: (a) volume; (b) N-acetylaspartate; and (c) fractional anisotropy levels in long-term cannabis users
and non-using controls. Controls (n= 37) are shown in red. Long-term cannabis users (n= 74) comprise three groups: CBDx, those with
unknown exposure to CBD (n= 19, in brown); CBD− , those known to be exposed to THC but not to CBD (n= 30, in green); and CBD+, those
exposed to both THC and CBD (n= 12, in orange). Former Users, former long-term cannabis users, abstinent for a mean 29 months (n= 13, in
blue). Horizontal lines represent group means and horizontal bars are the 95% confidence interval. *Po0.05; **Po0.005. Lower panels
illustrate the curve-fitting and polynomial contrasts that were applied to the data across the five groups to model our investigational aims.
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